ZhuZhou QianJin Pharmaceutical Co.,Ltd
Sembol: 600479.SS
SHH
10.91
CNYBugünkü piyasa fiyatı
17.7362
F/K Oranı
12.5927
PEG Oranı
4.56B
MRK Kapağı
- 0.03%
DIV Verimi
ZhuZhou QianJin Pharmaceutical Co.,Ltd (600479-SS) Finansal Tablolar
Bilanço
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 6888.47 | 1997.9 | 1731.7 | 1369.7 | |||||||||||||||||||||||
balance-sheet.row.short-term-investments | -97.51 | -45.7 | 491.7 | 736.8 | |||||||||||||||||||||||
balance-sheet.row.net-receivables | 4356.41 | 967 | 983.9 | 921.6 | |||||||||||||||||||||||
balance-sheet.row.inventory | 2227.63 | 534.1 | 599 | 547.8 | |||||||||||||||||||||||
balance-sheet.row.other-current-assets | 281.2 | 15.4 | 198.9 | 78.1 | |||||||||||||||||||||||
balance-sheet.row.total-current-assets | 13753.71 | 3514.5 | 3513.5 | 2917.3 | |||||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 2371.59 | 589.9 | 622.8 | 630.2 | |||||||||||||||||||||||
balance-sheet.row.goodwill | 56.3 | 14.1 | 14.1 | 14.1 | |||||||||||||||||||||||
balance-sheet.row.intangible-assets | 906.1 | 238.3 | 221.8 | 219.6 | |||||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 962.39 | 252.3 | 235.9 | 233.7 | |||||||||||||||||||||||
balance-sheet.row.long-term-investments | 965.47 | 293.3 | -304.1 | -546.1 | |||||||||||||||||||||||
balance-sheet.row.tax-assets | 68.79 | 22.7 | 6.6 | 4.1 | |||||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 141.8 | 4.2 | 547.3 | 821 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 4510.04 | 1162.4 | 1108.5 | 1143 | |||||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.total-assets | 18263.75 | 4676.9 | 4622 | 4060.2 | |||||||||||||||||||||||
balance-sheet.row.account-payables | 2617.36 | 647.5 | 780.9 | 511.7 | |||||||||||||||||||||||
balance-sheet.row.short-term-debt | 279.3 | 78.2 | 79.5 | 88.6 | |||||||||||||||||||||||
balance-sheet.row.tax-payables | 218.03 | 70.6 | 72.5 | 35.6 | |||||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 144.84 | 38.5 | 44.8 | 60.3 | |||||||||||||||||||||||
Deferred Revenue Non Current | 155.79 | 38 | 44.4 | 51.3 | |||||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 78.35 | - | - | - | |||||||||||||||||||||||
balance-sheet.row.other-current-liab | 280.05 | 69.1 | 705.6 | 75.5 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 407.36 | 108.3 | 108.5 | 131.9 | |||||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 110.84 | 31.5 | 32.8 | 44.8 | |||||||||||||||||||||||
balance-sheet.row.total-liab | 6493.32 | 1650.1 | 1805.7 | 1360.3 | |||||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.common-stock | 1716.69 | 428.9 | 429.8 | 418.5 | |||||||||||||||||||||||
balance-sheet.row.retained-earnings | 4286.33 | 1142.5 | 970.8 | 930.7 | |||||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2362.59 | 280.8 | 275.3 | 298.1 | |||||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 933.42 | 537.5 | 540.3 | 503 | |||||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 9299.03 | 2389.7 | 2216.2 | 2150.4 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 18263.75 | 4676.9 | 4622 | 4060.2 | |||||||||||||||||||||||
balance-sheet.row.minority-interest | 2471.4 | 637.1 | 600.1 | 549.5 | |||||||||||||||||||||||
balance-sheet.row.total-equity | 11770.43 | 3026.8 | 2816.3 | 2699.9 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 18263.75 | - | - | - | |||||||||||||||||||||||
Total Investments | 867.96 | 247.6 | 187.6 | 190.8 | |||||||||||||||||||||||
balance-sheet.row.total-debt | 424.14 | 116.7 | 124.2 | 148.9 | |||||||||||||||||||||||
balance-sheet.row.net-debt | -6414.01 | -1881.2 | -1115.7 | -484 |
Nakit Akış Tablosu
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 278.61 | 395 | 388.3 | 374.7 | ||||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 14.07 | 103.7 | 95.6 | 85.9 | ||||||||||||||||||||||
cash-flows.row.deferred-income-tax | -73.79 | -2.8 | -3.6 | 2.7 | ||||||||||||||||||||||
cash-flows.row.stock-based-compensation | 18.19 | 2.8 | 3.6 | -2.7 | ||||||||||||||||||||||
cash-flows.row.change-in-working-capital | 53.6 | -81.7 | 246.9 | 65.8 | ||||||||||||||||||||||
cash-flows.row.account-receivables | -8.69 | -8.7 | -163.7 | 275.9 | ||||||||||||||||||||||
cash-flows.row.inventory | 62.29 | 62.3 | -51.2 | -52.4 | ||||||||||||||||||||||
cash-flows.row.account-payables | 0 | -132.5 | 465.4 | -160.4 | ||||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -2.8 | -3.6 | 2.7 | ||||||||||||||||||||||
cash-flows.row.other-non-cash-items | 191.12 | 26.1 | 2.7 | -40.9 | ||||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 474.21 | 0 | 0 | 0 | ||||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -36.4 | -44 | -34.4 | -71.9 | ||||||||||||||||||||||
cash-flows.row.acquisitions-net | 0.06 | 0 | 0.2 | 30.8 | ||||||||||||||||||||||
cash-flows.row.purchases-of-investments | -100.06 | -402 | -2102 | -1570 | ||||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 357.66 | 1031.2 | 2258.4 | 1567.7 | ||||||||||||||||||||||
cash-flows.row.other-investing-activites | 75.41 | 0.1 | 0 | 0 | ||||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 221.32 | 585.3 | 122.1 | -43.3 | ||||||||||||||||||||||
cash-flows.row.debt-repayment | -50.72 | -50.7 | -15 | -127.6 | ||||||||||||||||||||||
cash-flows.row.common-stock-issued | 1.41 | 0 | 0 | 0 | ||||||||||||||||||||||
cash-flows.row.common-stock-repurchased | -3.38 | 0 | 0 | 0 | ||||||||||||||||||||||
cash-flows.row.dividends-paid | -165.13 | -147.9 | -248.6 | -429.5 | ||||||||||||||||||||||
cash-flows.row.other-financing-activites | -17.62 | -13.1 | -0.5 | 36.5 | ||||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -219.51 | -202 | -264.2 | -520.6 | ||||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -8.88 | 0 | 0 | 0 | ||||||||||||||||||||||
cash-flows.row.net-change-in-cash | 467.14 | 826.4 | 591.4 | -78.3 | ||||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 6497.52 | 1928.3 | 1101.9 | 510.5 | ||||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 6030.38 | 1101.9 | 510.5 | 588.8 | ||||||||||||||||||||||
cash-flows.row.operating-cash-flow | 474.21 | 443.1 | 733.5 | 485.6 | ||||||||||||||||||||||
cash-flows.row.capital-expenditure | -36.4 | -44 | -34.4 | -71.9 | ||||||||||||||||||||||
cash-flows.row.free-cash-flow | 437.81 | 399.1 | 699 | 413.7 |
Gelir Tablosu Satırı
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3839.03 | 3798.5 | 4026.3 | 3663.8 | |||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 2054.9 | 2046.7 | 2289.9 | 2032.2 | |||||||||||||||||||||||
income-statement-row.row.gross-profit | 1784.14 | 1751.8 | 1736.4 | 1631.6 | |||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.research-development | 185.64 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 68.58 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 884.41 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-expenses | -840.99 | -3337.9 | 218.6 | 189.1 | |||||||||||||||||||||||
income-statement-row.row.operating-expenses | 1892.94 | 3337.9 | 1311.7 | 1261.1 | |||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 3399.17 | 3337.9 | 3601.5 | 3293.4 | |||||||||||||||||||||||
income-statement-row.row.interest-income | 48.46 | 51.4 | 9.8 | 11.9 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 1.26 | 1.7 | 2.2 | 2.1 | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 884.41 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -1.23 | -1.5 | 1.6 | -2.8 | |||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -840.99 | -3337.9 | 218.6 | 189.1 | |||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -1.23 | -1.5 | 1.6 | -2.8 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 1.26 | 1.7 | 2.2 | 2.1 | |||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | -79.84 | 103.7 | 104.2 | 47.3 | |||||||||||||||||||||||
income-statement-row.row.ebitda-caps | 486.32 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.operating-income | 465.79 | 460.6 | 444.2 | 436.2 | |||||||||||||||||||||||
income-statement-row.row.income-before-tax | 464.56 | 459.1 | 445.8 | 433.4 | |||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 66.62 | 65.4 | 57.6 | 58.7 | |||||||||||||||||||||||
income-statement-row.row.net-income | 278.61 | 320.4 | 302.5 | 302.1 |
Sıkça Sorulan Sorular
Nedir ZhuZhou QianJin Pharmaceutical Co.,Ltd (600479.SS) toplam varlıklar?
ZhuZhou QianJin Pharmaceutical Co.,Ltd (600479.SS) toplam varlıklar 4676882466.000 şeklindedir.
İşletmenin yıllık geliri nedir?
Yıllık gelir 2020321390.000'dur.
Firma kâr marjı nedir?
Firma kar marjı 0.465'dir.
Şirket serbest nakit akışı nedir?
Serbest nakit akışı 1.021'dur.
İşletme net kar marjı nedir?
Net kâr marjı 0.073'dir.
Firma toplam geliri nedir?
Toplam gelir 0.121'dur.
Nedir ZhuZhou QianJin Pharmaceutical Co.,Ltd (600479.SS) net kar (net gelir)?
Net kar (net gelir) 320405834.000'dur.
Firmanın toplam borcu nedir?
Toplam borç 116705915.000'dir.
Faaliyet giderleri rakamı nedir?
İşletme giderleri 3337921320.000'dır.
Şirket nakit rakamı nedir?
İşletme içi nakit 1800315939.000'tir.